Market research
OVID Ovid Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 547M
- P/E ratio
- Not available
- Analyst target
- 5.6933
- Dividend yield
- Not available
- Beta
- 0.23
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6904691010
- Market cap
- 547M
- P/E ratio
- Not available
- Analyst target
- 5.6933
- Dividend yield
- Not available
- Beta
- 0.23
About
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OVID discussion.
5 years, 4 months ago
Ovid Therapeutics Inc is currently in a long term downtrend where the price is trading 1.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.5.
Ovid Therapeutics Inc's total revenue rose by inf% to $6M since the same quarter in the previous year.
Its net income has dropped by 29.8% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.9% to $-15M since the same quarter in the previous year.
Based on the above factors, Ovid Therapeutics Inc gets an overall score of 3/5.